Active U.S. drug shortages rose to 227 in the second quarter of 2026, the third consecutive quarterly increase, according to the American Society of Health-System Pharmacists. Nearly half of new shortages this year involve products made by a single manufacturer,…

CVS Pharmacy has agreed to pay $315 million to resolve Justice Department allegations that it illegally filled opioid and other controlled substance prescriptions, according to an Oct. 13 news release. Here are five things to know:

Four House lawmakers, Reps. Rob Bresnahan, R-Pa., Debbie Dingell, D-Mich., Tracey Mann, R-Kan., and Lois Frankel, D-Fla., have introduced bipartisan legislation that would pause HRSA’s 340B rebate model pilot. Here are six things to know:

California has invested $3.6 million to launch PRIME Rx at the University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, the first Programs in Medical Education (PRIME) program at a pharmacy school. It aims to train pharmacists…

Sacramento, Calif.-based Sutter Health’s Alta Bates Summit Medical Center in Oakland, Calif., has been named an ASHP Certified Center of Excellence in Medication-Use Safety and Pharmacy Practice, becoming the first Sutter medical center to earn the designation. The designation recognizes…

Health systems told CMS in public comment letters how much its proposed cut to 340B drug payments would cost them, with estimates ranging from about $7 million to $109 million a year. The 2027 outpatient payment rule, proposed July 2,…

Drug diversion creates consequences that extend far beyond pharmacy operations. Legal, compliance, nursing, risk management, human resources, and executive teams are often pulled into lengthy investigations and remediation efforts. As health systems face increasing regulatory scrutiny and financial pressures, diversion…

The FDA has approved Teva Pharmaceuticals’ Weltruza (olanzapine) for extended-release injectable suspension to treat schizophrenia in adults. Weltruza is the first and only once-monthly subcutaneous long-acting injectable formulation of olanzapine, according to an Oct. 9 news release. The treatment requires…

From the first lawsuit to Lilly's ultimatum: 18 months that reshaped the 340B program.

A September analysis by consulting firm 3 Axis Advisors, completed on behalf of Mark Cuban Cost Plus Drug Co., compared the company’s prices with what pharmacy benefit managers charged 13 commercial employer plans for the same drugs in 2024. Here…